This HTML5 document contains 78 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n9http://dx.doi.org/10.1016/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q72623669
rdf:type
wikibase:Item
schema:description
scientific article published on 01 March 1995 bài báo khoa học article scientifique publié en 1995 im März 1995 veröffentlichter wissenschaftlicher Artikel наукова стаття, опублікована в березні 1995 artículu científicu espublizáu en marzu de 1995 wetenschappelijk artikel
p:P577
wds:Q72623669-4B13B8F9-733E-4907-9102-D43B5354B868
wdt:P577
1995-03-01T00:00:00Z
p:P407
wds:Q72623669-BD4465C5-7324-4E6E-AF9A-93E5D9E3B36A
wdt:P407
wd:Q1860
p:P2860
wds:Q72623669-8C40DBBF-7E5C-49A6-B7C9-70DBC76C9C33 wds:Q72623669-99AE75E3-BE62-4468-A2C2-C3CD2179D290 wds:Q72623669-9B98F28E-2073-4BB1-B9F0-10E8EA38D9F6 wds:Q72623669-545D01E3-3A59-499A-9F35-FD70400AB88F wds:Q72623669-553B7705-10F6-4E0C-BBBF-91DCC2C27894 wds:Q72623669-5A8F35D4-5AE1-4F95-AC4F-21DF0B5A7564 wds:Q72623669-07548FF1-8D2A-4B30-A10F-22F292825D05 wds:Q72623669-08C680C2-A820-4A4B-AFA2-064BA76A1F80 wds:Q72623669-232C9663-0B7C-4ADC-81ED-51A02D0D29A8 wds:Q72623669-C1247489-7EE6-4354-8B50-E0623F91FED9 wds:Q72623669-C4AA60C2-18C1-45B1-A026-D09F35D11F8B wds:Q72623669-FAEAFAD4-500C-4F61-82C2-E1BCE54003C2 wds:Q72623669-6D0D0D79-9E4E-4D4A-9567-A16065D8557F
wdt:P2860
wd:Q44023156 wd:Q34541247 wd:Q70676591 wd:Q70147507 wd:Q34564820 wd:Q44924363 wd:Q67902425 wd:Q34336722 wd:Q72182215 wd:Q67733226 wd:Q70060438 wd:Q72885518 wd:Q33610275
p:P2093
wds:Q72623669-40CB86F1-C899-448A-9549-1EFA90BCED4D wds:Q72623669-34119AE5-62C8-4B42-B1F2-CB9D73BEFEE3 wds:Q72623669-A6E0A706-348A-4021-B27F-E361A8BECB5D wds:Q72623669-D8EEB556-8022-40B0-8D2D-94AFDB7E98DF wds:Q72623669-C2D40082-4D3C-4927-BE85-A230C40047C7
wdt:P2093
K Anderson H F Weisman K N Sigmon D J Moliterno F V Aguirre
rdfs:label
Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complicatio Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy
skos:prefLabel
Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complicatio
schema:name
Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complicatio
p:P50
wds:Q72623669-34E74F61-9E98-4C72-A6C8-36FE76190144 wds:Q72623669-477006CA-10D7-400D-88E1-6B495C6A9611
wdt:P50
wd:Q5387640 wd:Q19281782
p:P1476
wds:Q72623669-B62E5149-5173-4DE2-9A52-7EEFB65FE499
wdt:P1476
Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial
p:P304
wds:Q72623669-5ED303F4-DD0A-4FCC-BBF4-60CEA96DDC10
wdt:P304
559-562
p:P31
wds:Q72623669-5EDB99BE-E7E0-4094-9D9B-EADD05F06530
wdt:P31
wd:Q13442814
p:P921
wds:Q72623669-5F7F32FB-5F7A-424D-B3BC-8B4EA4FE7274
wdt:P921
wd:Q539795
p:P698
wds:Q72623669-CBD08AB2-793C-4959-9AD6-3BAF8E088017
wdtn:P698
n11:7887377
wdt:P698
7887377
p:P1433
wds:Q72623669-682587C5-819C-4AE9-9D08-7CBDC9E7381E
wdt:P1433
wd:Q2208417
p:P433
wds:Q72623669-ECF1388C-332D-4332-84D4-0D91544C3BB9
p:P478
wds:Q72623669-A436465F-844C-4BD0-8823-82B015FF0C80
wdt:P433
8
wdt:P478
75
p:P356
wds:Q72623669-DDE50A8F-09A1-4777-8128-530D719C70E8
wdtn:P356
n9:S0002-9149(99)80616-X
wdt:P356
10.1016/S0002-9149(99)80616-X